Petrelintide (ZP8396) Petrelintide (ZP8396) is a novel SC-administered, long-acting amylin analog, developed by Zealand Pharma (Sborg, Denmark), a peptide drug discovery and development company, which is currently in early-stage clinical trials (phase 1 clinical trials: ClinicalTrials.gov Identifier NCT05511025, NCT05096598 and NCT05613387) [116]
About this article Cite this article Atanasova, K., Reznikov, L
By stimulating collagen manufacturing, these peptides assist in rebuilding damaged tissues and promoting general recovery
Leqvio +114% cc Key Peptide Products: Lutathera (lutetium-177 DOTATATE, oncology peptide receptor radionuclide), Pluvicto (177Lu-PSMA-617), Sandostatin/Signifor (octreotide/pasireotide somatostatin analogues), Leqvio (inclisiran siRNA, category-adjacent) Therapeutic Segments: Oncology (radioligand therapy, CDK4/6 inhibitors)
Business Type Exporter, Manufacturer, Supplier, Trading Company Employee Count 10 Establishment 2019 Working Days To GST NO 27AARFV7394M1ZY Payment Mode Online Payments (NEFT/RTGS/IMPS), Cheque/DD, Wallet & UPI, Cash Related Products Explore Related Categories More Products From This Seller Seller Details GST - 27AARFV7394M1ZY Trusted Seller Mumbai, Maharashtra Sales Manager Mr
